May 31, 2022 – Understanding the tradeoffs among desirable and undesirable drug product characteristics that consumers and their treating physicians make “will provide valuable insight into the relevance and impact of various product attributes and promotional claims on informed choices and treatment decisions,” according to the Food and Drug Administration’s Office of Prescription Drug Promotion […]
Read moreMay 2, 2014 – The Coalition for Healthcare Communication believes that “shorter, simpler disclosures are most likely to lead to robust doctor-patient conversations and better health outcomes,” according to a comment the CHC submitted to the FDA today on its proposal to conduct research on the impact of limiting risks presented in direct-to-consumer (DTC) prescription […]
Read moreFeb. 17, 2014 – In recognition that the stream of risks currently disclosed on direct-to-consumer (DTC) television ads may be so detailed that they have become white noise, the FDA is announcing in the Federal Register due to be published Feb. 18 (2014-03390) that it will study what impact limiting those risks to the most serious […]
Read more